MS Paris

Robert Zivadinov, MD, discussed how the results of the TOPIC study will impact clinical practice for those specializing in mutliple sclerosis, and what doctors should look for while caring for patients with MS.

Ruth Ann Marrie, MD, PhD, FRCP, discussed what it's like to treat patients with multiple sclerosis from a team-based approach, as well as what needs to be done to address the issues faced by patients with MS that also have comorbidities.

Robert Zivadinov, MD, discussed the remaining question about Aubagio's mechanism of action after collecting data from the TOPIC study.

Attendees at MS Paris 2017 discussed the biggest unmet needs in treating multiple sclerosis.

John Corboy, MD, discussed how there is a lack of knowledge on when and why to stop using disease-modifying therapies with MS patients.

Data from the TEMSO study has shown that Aubagio can significantly improve PASAT-3 scores.

Robert Zivadinov, MD, spoke about the results of the TOPIC study and how cortical gray matter atrophy is associated with conversion to clinically definite MS.

John Corboy, MD, discussed the challenges of collecting data about how stopping disease-modifying therapies affects patients with MS.

Bruce Cree, MD, PhD, spoke about the connection between brain volume loss and disability progression in patients with MS in the long term.

Ibudilast slowed the rate of brain atrophy by 48% without inducing significant toxicity for progressive MS.

Teriflunomide was an effective first-line therapy for RRMS and a suitable switch therapy in real-world data.

The TOPIC study results additionally showed a strong association between CGMV loss and CDMS conversion.

Aaron Boster, MD, spoke about the efforts and his involvement in the MS Paths program.

Tanuja Chitnis, MD, spoke about the first-of-its-kind PARADIGMS trial, and pediatric multiple sclerosis, as well as how it differs from the condition in adults.

The PARADIGMS data showed an 81.9% reduction in the rate of annualized relapses.

Ozanimod reduced the annualized relapse rate and lowered the number of T2 lesions versus interferon beta-1a for RMS.

Ozanimod reduced ARR and showed marked reductions in T2 lesions compared with interferon β-1a for RMS.

Subgroup analysis revealed a greater improvement for patients with baseline visual impairment.

Alemtuzumab showed significant reductions in MRI lesions and slowed brain volume loss in 5-year results for RRMS.

Francisco Quintana, MD, spoke about his efforts to identify new drugs for treating multiple sclerosis and how reliable biomarkers are the biggest need in treating MS.

Nearly all patients with relapsing multiple sclerosis treated with ublituximab remained relapsed free after 24 weeks.

Ruth Ann Marrie, MD, PhD, FRCP, spoke about the prevalence of comorbidities in patients with MS, and how these patients are often overlooked and left out of clinical trials.

Martin Weber, MD, spoke about the role that B cells and antibodies play in the treatment of multiple sclerosis.

MD1003 led to a pseudo-atrophy phenomenon that was likely related to remyelination.

The EXPAND trial results supported the potential neuroprotective effects of siponimod.